ANTICOAGULANTS IN ATRIAL FIBRILLATION
Abstract
The results of studies of the use of the anticoagulant and antiaggregant therapy for prevention of throboembolism due to atrial fibrillation are considered. The information regarding the development of novel anticoagulants is given.
About the Author
A. Yu. Rychkov
Филиал НИИК ТНЦ СО РАМН «Тюменский кардиологический центр»
Russian Federation
Russian Federation
References
1. Рекомендации Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции по проведению клинических электрофизиологических исследований, катетерной аблации и имплантации антиаритмических устройств. - М.: Изательский дом «Золотой абрикос», 2005. - 240 с.
2. Федеральное руководство по использованию лекарственных средств (формулярная система. Выпуск VIII. - М.: «Эхо», 2007.- 1000 с.
3. ACTIVE-W: warfarin beats clopidogrel/aspirin in atrial fibrillation.// Cardiovascular Journal of South Africa. - 2006. - V. 17. - N. 2. - P. 91.
4. Akins P.T. et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials // Stroke. - 2007. - V.38. - P. 874-880.
5. Aguilar M, Hart R, Pearce L. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.//Cochrane Database Syst Rev. - 2007. - 18; 3: CD006186.
6. Bauer K.A. New Anticoagulants.// Hematology. - 2006. - P. 450-456.
7. De Caterina R. et al. Anticoagulants in heart disease: current status and perspectives.// Eur Heart J. - 2007. -V.28. - P.880-913.
8. Douketis D.J. et al. Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin.// Arch Intern Med. - 2006. - V.166. - P. 853-859.
9. Fuster V. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).// Circulation. - 2006. - V.114. - P.e257-e354.
10. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation.// Ann Intern Med. -2007. - V. 146, - P. 857-867.
11. Testa L. et al. Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients.// Int J Cardiol. - 2007. - Articles in Press
12. Turpie A.G.G. Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases.// Arterioscler Thromb Vasc Biol. -2007. - V.27. - P. 1238-1247.
13. Verheugt F.W.A. Stroke prevention in atrial fibrillation.// Netherlands J Med. - 2006. - V. 64. - P. 31-33.
14. Wysowski D.K., Nourjah P., Swartz L. Bleeding Complications With Warfarin Use A Prevalent Adverse Effect Resulting in Regulatory Action.// Arch Intern Med. - 2007. - V.167. - P.1414-1419.
Review
For citations:
Rychkov A.Yu. ANTICOAGULANTS IN ATRIAL FIBRILLATION. Journal of Arrhythmology. 2007;(50):46-49. (In Russ.)
Views:
146
Email this article 